Nuclear Pharmaceuticals Private Limited
About Nuclear Pharmaceuticals Private Limited
Data last updated:
Nuclear Pharmaceuticals Private Limited is a private limited company based in Sangliwadi, Maharashtra, India. It operates in the specialised services segment of the trading and commerce sector. It was incorporated on 27 February 2017 and has been in existence for over 9 years.
The company is registered with the Registrar of Companies (ROC), Pune, under CIN U51909PN2017PTC169111. Its GSTIN is 27AAFCN5140A1ZX (Maharashtra).
The company has an authorised share capital of ₹10 Lakh and a paid-up capital of ₹2.6 Lakh. It is led by directors Priyanka Ganpatarav Pachunde and Satish Ganpati Chavan.
Its last annual general meeting (AGM) was held on 30 September 2025, and its latest financial statements are for the year ended 31 March 2025. The registered office is at C/O Satish Ganpati Chavan S.No.269/1A/2 Magadum Plot Islampur Road, Sangliwadi, Maharashtra, India – 416416.
As per the financials filed for FY 2025, the company reported a revenue of ₹53.46 Lakh, a growth of 8% compared to the previous year. For the same year it recorded a net profit of ₹31,260 (net margin 0.6%) and EBITDA of ₹54,370 (EBITDA margin 1%). Revenue has grown at a compounded annual rate (CAGR) of 26% over three years and 27% over five years.
The current compliance status is marked as compliant by the Registrar of Companies.
- EmailLocked
- TelephoneLocked
- WebsiteLocked
- Social MediaLocked
- Registered AddressC/O Satish Ganpati Chavan S.No.269/1A/2 Magadum Plot Islampur Road, Sangliwadi, Maharashtra, India – 416416
- IndustryTrading, Specialty, Wholesale
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
- One PDF report, delivered after checkout
Business Activity of Nuclear Pharmaceuticals Private Limited
The main business activity of Nuclear Pharmaceuticals is manufacturing. In detail, this covers manufacture of basic pharmaceutical products and pharmaceutical preparations.
| Main Activity Group Code | Description of Main Activity | Business Activity Code | Description of Business Activity | Turnover Percentage |
|---|---|---|---|---|
| C | Manufacturing | 21 | Manufacture of basic pharmaceutical products and pharmaceutical preparations | Locked |
Business activity turnover details
Turnover share and past changes in activity are in the company report.
- Turnover contribution
- Historical classifications
- Filing-level activity changes
Verified entity values are shown only after access is granted.
Financials of Nuclear Pharmaceuticals Private Limited FY 2025 filings available
Nuclear Pharmaceuticals Private Limited reported revenue of ₹53.46 Lakh (up 8% YoY) for FY 2025.
Compounded Annual Growth Rate (CAGR) of Nuclear Pharmaceuticals Private Limited
Revenue has grown at a compounded annual rate (CAGR) of 27% over five years, including 8% growth in the latest year. EBITDA fell 9% in the latest year. Three- and five-year figures are compounded annual growth rates (CAGR): the steady yearly rate that links the first and the last year. All are worked out from the filed statements.
Financial Statement Summary of Nuclear Pharmaceuticals Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profit and Loss Statement | |||||
| Revenue from Operations | •••• | •••• | •••• | •••• | •••• |
| Other Income | •••• | •••• | •••• | •••• | •••• |
| Total Revenue | •••• | •••• | •••• | •••• | •••• |
| Cost of Materials Consumed | •••• | •••• | •••• | •••• | •••• |
| Employee Benefit Expense | •••• | •••• | •••• | •••• | •••• |
| Finance Costs | •••• | •••• | •••• | •••• | •••• |
| Depreciation and Amortisation | •••• | •••• | •••• | •••• | •••• |
| Other Expenses | •••• | •••• | •••• | •••• | •••• |
| Total Expenses | •••• | •••• | •••• | •••• | •••• |
| EBITDA | ₹54,370 | •••• | •••• | •••• | •••• |
| Profit Before Tax | •••• | •••• | •••• | •••• | •••• |
| Tax Expense | •••• | •••• | •••• | •••• | •••• |
| Net Profit (PAT) | ₹31,260 | •••• | •••• | •••• | •••• |
| Balance Sheet | |||||
| Share Capital | •••• | •••• | •••• | •••• | •••• |
| Reserves and Surplus | •••• | •••• | •••• | •••• | •••• |
| Net Worth (Total Equity) | •••• | •••• | •••• | •••• | •••• |
| Long-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Short-term Borrowings | •••• | •••• | •••• | •••• | •••• |
| Trade Payables | •••• | •••• | •••• | •••• | •••• |
| Total Liabilities | •••• | •••• | •••• | •••• | •••• |
| Fixed Assets | •••• | •••• | •••• | •••• | •••• |
| Investments | •••• | •••• | •••• | •••• | •••• |
| Inventories | •••• | •••• | •••• | •••• | •••• |
| Trade Receivables | •••• | •••• | •••• | •••• | •••• |
| Cash and Bank Balance | •••• | •••• | •••• | •••• | •••• |
| Total Assets | •••• | •••• | •••• | •••• | •••• |
Financial Ratios of Nuclear Pharmaceuticals Private Limited
| Metrics | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 |
|---|---|---|---|---|---|
| Profitability | |||||
| EBITDA Margin | 1% | •••• | •••• | •••• | •••• |
| Net Profit Margin | 0.6% | •••• | •••• | •••• | •••• |
| Return on Equity (ROE) | •••• | •••• | •••• | •••• | •••• |
| Return on Capital Employed (ROCE) | •••• | •••• | •••• | •••• | •••• |
| Return on Assets (ROA) | •••• | •••• | •••• | •••• | •••• |
| Liquidity and Debt | |||||
| Current Ratio | •••• | •••• | •••• | •••• | •••• |
| Quick Ratio | •••• | •••• | •••• | •••• | •••• |
| Debt-to-Equity Ratio | •••• | •••• | •••• | •••• | •••• |
| Interest Coverage Ratio | •••• | •••• | •••• | •••• | •••• |
| Efficiency and Growth | |||||
| Asset Turnover | •••• | •••• | •••• | •••• | •••• |
| Receivable Days | •••• | •••• | •••• | •••• | •••• |
| Payable Days | •••• | •••• | •••• | •••• | •••• |
| Inventory Days | •••• | •••• | •••• | •••• | •••• |
| Revenue Growth | •••• | •••• | •••• | •••• | •••• |
| Net Profit Growth | •••• | •••• | •••• | •••• | •••• |
Paid data: the figures shown as dots are available after purchase of the company report. Figures as filed with the MCA in Form AOC-4. The full year-wise statements and ratios of Nuclear Pharmaceuticals are in the company report.
Financial statements from FY 2017
Earlier years and trend charts are in the company report.
- Income statements
- Balance sheets
- Cash-flow statements
- Ratios and benchmarks
Verified entity values are shown only after access is granted.
Board of Directors of Nuclear Pharmaceuticals Private Limited
Nuclear Pharmaceuticals has 2 directors on record. No former directors are listed.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Priyanka Ganpatarav Pachunde | Director | 27 Feb 2017 | 9 Years 7 Months | Current |
| Satish Ganpati Chavan | Director | 27 Feb 2017 | 9 Years 7 Months | Current |
Peer Comparison of Nuclear Pharmaceuticals Private Limited
Nuclear Pharmaceuticals Private Limited is compared with the companies closest to it by revenue in the Pharma industry (Pharmaceuticals). Net profit, margin and employee counts of each company are in the company report.
| Company | Revenue | Net profit | Margin | Growth (1 yr) | Employees | Location |
|---|---|---|---|---|---|---|
| Daily Dose Pharmaceuticals Private Limited | ₹54 Lakh (FY 2025) | •••• | •••• | 18.0% | •••• | Nashik, Maharashtra, India |
| Kiara Pharmaceuticals Private Limited | ₹53.87 Lakh (FY 2024) | •••• | •••• | •••• | Ahmedabad, Gujarat, India | |
| Nannu's Pharmaceuticals Private Limited | ₹53.6 Lakh (FY 2024) | •••• | •••• | -30.0% | •••• | Nagpur, Maharashtra, India |
| Xyoza Pharmaceuticals Private Limited | ₹53.53 Lakh (FY 2025) | •••• | •••• | 53.0% | •••• | Mohali, Punjab, India |
| Novonortia Pharmaceuticals Private Limited | ₹53.46 Lakh (FY 2025) | •••• | •••• | •••• | Aligarh, Uttar Pradesh, India | |
| Nuclear Pharmaceuticals Private Limited this company | ₹53.46 Lakh (FY 2025) | •••• | •••• | 8.0% | •••• | Sangliwadi, Maharashtra, India |
| Exelkem India Pharmaceuticals Private Limited | ₹53.32 Lakh (FY 2024) | •••• | •••• | 432.0% | •••• | Lucknow, Uttar Pradesh, India |
| Humanlife Pharmaceuticals Private Limited | ₹53.28 Lakh (FY 2025) | •••• | •••• | -18.0% | •••• | Mumbai, Maharashtra, India |
| Grown Pharmaceuticals Private Limited | ₹53.28 Lakh (FY 2024) | •••• | •••• | 0.0% | •••• | Patna, Bihar, India |
| Eltor Pharmaceuticals Private Limited | ₹53.07 Lakh (FY 2025) | •••• | •••• | 9.0% | •••• | Mumbai, Maharashtra, India |
| Opinor Pharmaceuticals Private Limited | ₹52.84 Lakh (FY 2025) | •••• | •••• | •••• | Hyderabad, Telangana, India |
Peers are the five companies nearest above and the five nearest below Nuclear Pharmaceuticals by revenue in the Pharma industry (Pharmaceuticals), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.
Ownership and Shareholding of Nuclear Pharmaceuticals Private Limited
Shareholding and ownership data
Promoter, institutional, public and beneficial ownership figures are in the company report.
- Ownership categories
- Historical changes
- Group structure
- FII and DII holdings
Verified entity values are shown only after access is granted.
Charges & Borrowings of Nuclear Pharmaceuticals Private Limited
Nuclear Pharmaceuticals Private Limited does not have any charges (loans) registered with the Registrar of Companies.
Employees and EPFO Compliance at Nuclear Pharmaceuticals Private Limited
Employment history and EPFO contributions of people linked to Nuclear Pharmaceuticals.
Employee and EPFO history
Monthly headcount, contribution history and filing status are in the company report.
- Monthly headcount
- PF contributions
- ECR filing status
- Establishment history
Verified entity values are shown only after access is granted.
Recent Activity on Nuclear Pharmaceuticals Private Limited
Nuclear Pharmaceuticals Private Limited has 2 board changes on record since 2017: 2 appointments. The latest: Priyanka Ganpatarav Pachunde was appointed as Director on 27 Feb 2017.
Credit Ratings, Litigation & Regulatory Alerts for Nuclear Pharmaceuticals Private Limited
Credit ratings, litigation, and regulatory alerts
Credit ratings, court records and regulatory alerts are in the company report.
- Rating history
- Court and tribunal cases
- Regulatory alerts
- Director-linked violations
Verified entity values are shown only after access is granted.
MSME Payment Delays by Nuclear Pharmaceuticals Private Limited
MSME payment history
Amounts due to small suppliers, the reasons given and MSME-1 filings are in the company report.
- Outstanding amounts
- Delay periods and reasons
- MSME-1 filing history
- Vendor payment signals
Verified entity values are shown only after access is granted.
Subsidiaries & Group Companies of Nuclear Pharmaceuticals Private Limited
Corporate group structure
Parent, subsidiary, associate and joint venture records with holdings are in the company report.
- Parent company
- Subsidiaries and ownership
- Associates and joint ventures
- Entity investments
Verified entity values are shown only after access is granted.
GST Compliance of Nuclear Pharmaceuticals Private Limited
Nuclear Pharmaceuticals has 1 GST registration: 1 active.
| GSTIN | State | Status | Registered on |
|---|---|---|---|
| 27AAFCN5140A1ZX | Maharashtra | Active | 14 Dec 2017 |
GST registrations and filing compliance
State-wise GST registrations, return filing status and HSN or SAC codes are in the company report.
- GSTIN registrations
- State-wise filing status
- HSN and SAC details
- Tax jurisdiction records
Verified entity values are shown only after access is granted.
MCA Filings & Documents of Nuclear Pharmaceuticals Private Limited
MCA filings and documents
Filed forms, annual returns, financial statements and charge filings with their dates are in the company report.
- Incorporation documents
- Annual returns and statements
- Charge filings
- Complete filing index
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nuclear Pharmaceuticals Private Limited
Nuclear Pharmaceuticals is an active private limited company based in Sangliwadi, Maharashtra, India. The company works in specialty, within the trading industry. It was incorporated on 27 February 2017 (9+ years old) and is registered under CIN U51909PN2017PTC169111.
Nuclear Pharmaceuticals reported revenue of ₹53.46 Lakh for FY 2025 (up 8% YoY).
Nuclear Pharmaceuticals has 2 current directors:
- Priyanka Ganpatarav Pachunde - Director
- Satish Ganpati Chavan - Director
Nuclear Pharmaceuticals reported a net profit of ₹31,260 (net margin 0.6%) and EBITDA of ₹54,370 (EBITDA margin 1%) for FY 2025, as per its filed financial statements.
The compounded annual growth rate (CAGR) of the revenue of Nuclear Pharmaceuticals is 26% over three years and 27% over five years. In the latest year (FY 2025) revenue rose 8%. CAGR is the steady yearly rate that links the first and the last year.
The GSTIN of Nuclear Pharmaceuticals is 27AAFCN5140A1ZX, registered in Maharashtra.
The CIN (Corporate Identification Number) of Nuclear Pharmaceuticals is U51909PN2017PTC169111. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Nuclear Pharmaceuticals was incorporated on 27 February 2017, making it 9+ years old. It is registered with the Registrar of Companies, Pune.
The peers of Nuclear Pharmaceuticals by revenue are Daily Dose Pharmaceuticals Private Limited, Kiara Pharmaceuticals Private Limited, Nannu's Pharmaceuticals Private Limited, Xyoza Pharmaceuticals Private Limited, Novonortia Pharmaceuticals Private Limited and 5 more, all in the Pharma industry (Pharmaceuticals).
Priyanka Ganpatarav Pachunde was appointed as Director on 27 Feb 2017. Satish Ganpati Chavan was appointed as Director on 27 Feb 2017.
The registered office of Nuclear Pharmaceuticals is at CO Satish Ganpati Chavan S.No.2691A2 Magadum Plot Islampur Road, Sangliwadi, Maharashtra, India – 416416.